Skip to main content

Table 1 Table giving the absolute numbers of studies investigating selected criteria (EB subtype, route of administration, outcome measure). As some studies list two possibilities for distinct criteria, respective sums might exceed the total of studies

From: Small molecule drug development for rare genodermatoses – evaluation of the current status in epidermolysis bullosa

 

Publication (n = 52)

Database (n = 32)

Outcome measure

 Wound healing

11

24

 Blister reduction

29

8

 Pain

7

5

 Itch

12

2

 SCC

2

1

 Other

7

1

Route of administration

 Topical

16

21

 Oral

30

9

 i.v.

2

3

 Local injection

6

4

 Unknown

2

0

EB Subtype

 EB

2

15

 EBS

14

8

 JEB

6

2

 DEB

31

8

 unknown

1

0

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172